Carter T. Fields

2.3k citations

17 papers · 1.4k indexed · 1 hit paper · h-index 9

Impact in

Oncology top 5%
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Cancer Cells and Metastasis
Radiology, Nuclear Medicine and Imaging top 2%
- Monoclonal and Polyclonal Antibodies Research

Papers in ⓘ

Oncology 11
- HER2/EGFR in Cancer Research 11
- Cancer Treatment and Pharmacology 1
Radiology, Nuclear Medicine and Imaging 7
- Monoclonal and Polyclonal Antibodies Research 7
- Medical Imaging Techniques and Applications 1

Co-authors: Gail D. Lewis Phillips (9 shared papers)Mark X. Sliwkowski (7 shared papers)Kathryn L. Parsons (6 shared papers)Teemu T. Junttila (3 shared papers)Deepak Sampath (3 shared papers)Robert W. Akita (2 shared papers)Lori S. Friedman (1 shared paper)Michael Pickles (3 shared papers)
Journals: Cancer Research (5 papers)Cancer Cell (2 papers)Gastroenterology (2 papers)Clinical Cancer Research (1 paper)Journal of Veterinary Pharmacology and Therapeutics (1 paper)
Partner nations: United States United Kingdom Switzerland

In The Last Decade

Carter T. Fields

17 papers receiving 1.4k citations

Hit Papers

align trajectories log scale

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 2009 · 651 citations

Peers

Countries citing papers authored by Carter T. Fields

Since Specialization

Citations

This map shows the geographic impact of Carter T. Fields's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carter T. Fields with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carter T. Fields more than expected).

Fields of papers citing papers by Carter T. Fields

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carter T. Fields. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carter T. Fields. The network helps show where Carter T. Fields may publish in the future.

Co-authors

The 25 scholars most cited alongside Carter T. Fields, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Carter T. Fields Line = papers co-authored together Carter T. Fields links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work
1	Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Cancer Cell ·Teemu T. Junttila, Robert W. Akita, Kathryn L. Parsons, Carter T. Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski Hit paper breakdown →	2009	651
2	Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: Evidence for epistasis between 1p and IBD1 Proceedings of the National Academy of Sciences ·Judy H. Cho, Dan L. Nicolae, Leslee H. Gold, Carter T. Fields, Michele C. LaBuda, Patrick M. Rohal, Michael Pickles, Qin Li, Yifan Fu, Jasdeep Mann, Barbara S. Kirschner, Ethylin Wang Jabs, James L. Weber, Stephen B. Hanauer, Theodore M. Bayless, Steven R. Brant	1998	312
3	Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy Clinical Cancer Research ·Gail D. Lewis Phillips, Carter T. Fields, Guangmin Li, Donald Dowbenko, Gabriele Schaefer, Kathy D. Miller, Fabrice André, Howard A. Burris, Kathy S. Albain, Nadia Harbeck, Véronique Dièras, Diana Crivellari, Fang Ting Liang, Ellie Guardino, Steven R. Olsen, Lisa Crocker, Mark X. Sliwkowski	2013	148
4	Targeting LGR5 ⁺ cells with an antibody-drug conjugate for the treatment of colon cancer Science Translational Medicine ·Melissa R. Junttila, Weiguang Mao, Xi Wang, Bu-er Wang, Thinh Pham, John A. Flygare, Shang-Fan Yu, Sharon Yee, David M. Goldenberg, Carter T. Fields, Jeffrey Eastham‐Anderson, Mallika Singh, Rajesh Vij, Jo-Anne Hongo, Ron Firestein, Melissa M. Schutten, Kelly M. Flagella, Paul Polakis, Andrew G. Polson	2015	127
5	American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12 Gastroenterology ·Steven R. Brant, Yifan Fu, Carter T. Fields, Romulo Baltazar, Geoffrey Ravenhill, Michael Pickles, Patrick M. Rohal, Jasdeep Mann, Barbara S. Kirschner, Ethylin Wang Jabs, Theodore M. Bayless, Stephen B. Hanauer, Judy H. Cho	1998	116
6	Pharmacokinetics of a novel closantel/ivermectin injection in cattle Journal of Veterinary Pharmacology and Therapeutics ·L. Cromie, Mathieu Ferry, A. Couper, Carter T. Fields, Subhashni Taylor	2006	23
7	Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Cancer Cell ·Teemu T. Junttila, Robert W. Akita, Kathryn Parsons, Carter T. Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski	2011	16
8	N-acetyl-L-leucine for Niemann-Pick type C: a multinational double-blind randomized placebo-controlled crossover study Trials ·Taylor Fields, Tatiana Brémovà-Ertl, Ian Billington, GC Churchill, William Evans, Carter T. Fields, (unknown), R. Kay, Theresa Mathieson, Κyriakos Martakis, Marc C. Patterson, Frances M. Platt, Michael Factor, Michael Strupp	2023	13
9	223 Trastuzumab-DM1: mechanisms of action and mechanisms of resistance European Journal of Cancer Supplements ·G. Li, Carter T. Fields, Kathryn L. Parsons, Jingzhu Guo, Gail D. Lewis Phillips	2010	10
10	Abstract S3-6: Combination Therapy of the Novel PI3K Inhibitor GDC-0941 and Dual PI3K/mTOR Inhibitor GDC-0980 with Trastuzumab-DM1 Antibody Drug Conjugate Enhances Anti-Tumor Activity in Preclinical Breast Cancer Models In Vitro and In Vivo Cancer Research ·D. Sampath, Carter T. Fields, G Li, WW Prior, Kathryn L. Parsons, LS Friedman, GD. Lewis-Phillips	2010	5
11	Abstract 5607: Dual targeting of HER2: Enhanced antitumor efficacy of trastuzumab-DM1 combined with pertuzumab Cancer Research ·Carter T. Fields, Lisa Crocker, Mark X. Sliwkowski, Gail D. Lewis Phillips	2010	5
12	515 POSTER Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel European Journal of Cancer Supplements ·Teemu T. Junttila, Carter T. Fields, G. Li, Lisa Crocker, Kathryn L. Parsons, Leanne Berry, Klára Tótpál, Gail D. Lewis Phillips, Mark X. Sliwkowski	2008	5
13	Abstract 1207: Preclinical development of 2nd generation HER2-directed antibody-drug conjugates Cancer Research ·Gail D. Lewis Phillips, Guangmin Li, Jun Guo, Jeffrey Lau, Shang‐Fan Yu, Thomas H. Pillow, Byoung-Chul Lee, Jack Sadowsky, Melissa M. Schutten, Carter T. Fields, Mark X. Sliwkowski	2016	4
14	Abstract #3239: Enhanced in vitro and in vivo activity of trastuzumab-DM1 antibody-drug conjugate combined with GDC-0941, a small molecule inhibitor of PI3 kinase Cancer Research ·Carter T. Fields, Guangmin Li, Wei Wei Prior, Kathryn L. Parsons, Deepak Sampath, Gail D. Lewis Phillips	2009	3
15	A genome wide screen of Crohn's disease in a large pedigree shows evidence for linkages to chromosomes 11, 16, 8 and 15 Gastroenterology ·Steven R. Brant, Dan L. Nicolae, Michele C. LaBuda, Romulo Baltazar, Carter T. Fields, Geoffrey Ravenhill, Michael Pickles, Patrick M. Rohal, Ethylin Wang Jabs, Stephen B. Hanauer, Theodore M. Bayless, Judy H. Cho	1998	3
16	Abstract 1212: The dual action antibody MEHD7945A targeting EGFR and HER3 enhances chemotherapy induced cytotoxicity in vitro and in vivo Cancer Research ·Lisa Crocker, Carter T. Fields, Lily Shao, Mark X. Sliwkowski, Gail D. Lewis Phillips, Gabriele Schaefer	2012	2
17	86 Potent anti-tumor activity of T-DM1 antibody–drug conjugate in combination with chemotherapeutic agents in breast tumor cells European Journal of Cancer Supplements ·Kathryn L. Parsons, Carter T. Fields, Berton Gunter, Gary Phillips, Jay Tibbitts	2010	2

About Carter T. Fields

Carter T. Fields is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Gastroenterology, Small Animals and Pulmonary and Respiratory Medicine, having authored 17 papers that have together received 1.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Inflammatory Bowel Disease (3 papers), Lung Cancer Treatments and Mutations (2 papers), Coccidia and coccidiosis research (1 paper), Cancer Treatment and Pharmacology (1 paper), Breast Cancer Treatment Studies (1 paper) and Medical Imaging Techniques and Applications (1 paper). The work is most often cited by research in Oncology (811 citations), Radiology, Nuclear Medicine and Imaging (517 citations), Genetics (403 citations), Immunology (257 citations) and Immunology and Allergy (59 citations). Carter T. Fields has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Gail D. Lewis Phillips, Mark X. Sliwkowski, Kathryn L. Parsons, Teemu T. Junttila, Deepak Sampath, Robert W. Akita, Lori S. Friedman, Michael Pickles, Ethylin Wang Jabs and Judy H. Cho. Their work appears in journals such as Cancer Research, Cancer Cell, Gastroenterology, Clinical Cancer Research and Journal of Veterinary Pharmacology and Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact